Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
نویسندگان
چکیده
منابع مشابه
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
New strategies for profound inhibition of platelet activity at the injured coronary plaque focus on blockade of the platelet surface membrane glycoprotein IIb/IIIa receptor, which binds circulating fibrinogen or von Willebrand factor and crosslinks platelets as the final common pathway to platelet aggregation. Intravenous agents directed against this receptor include the chimeric monoclonal ant...
متن کاملPlatelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
BACKGROUND Platelet glycoprotein IIb/IIIa receptor blockade not only enhances epicardial flow but also improves microvascular perfusion. Inhibition of abnormal platelet-endothelial interactions may contribute to this beneficial effect. The present study was designed to determine whether glycoprotein IIb/IIIa receptor blockade influences endothelial vasomotor function and NO bioactivity in patie...
متن کاملPlatelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction associated with thrombotic occlusion of the left main coronary artery.
Several reports have recently opened a new therapeutic window for the use of platelet glycoprotein (GP) IIb/IIIa receptor blockade as an adjunct to thrombolytic therapy in acute myocardial infarction. Because of the different protocols and the different agents that were used, as well as the relatively small number of patients included in these studies, one cannot draw any definitive conclusions...
متن کاملMedical decision making with incomplete evidence--choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions.
BACKGROUND Medical decision making must often be performed despite incomplete evidence. An example is the choice of a glycoprotein IIb/IIIa (GP2b3a) inhibitor, a class of potent antiplatelet medications, as adjunctive therapy during percutaneous coronary interventions (PCIs). GP2b3a inhibitor efficacy in reducing adverse outcomes has been well documented with multiple placebo-controlled randomi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2000
ISSN: 0735-1097
DOI: 10.1016/s0735-1097(00)00554-4